Ticker: TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) - What's happening inside Quick read: Tonix is staging a commercial and R&D push ahead of a near-term FDA PDUFA date (TNX-102 SL - Aug 15, 2025) while managing legacy commercial products (Zembrace, Tosymra), sizable accumulated losses and ongoing...

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) recently released its quarterly financial report for the period ending March 31, 2025, reflecting significant operational and financial activities. Key Highlights: Revenue: Product revenues were $2.4 million in Q1 2025, slightly down from $2.5 m...

Tonix Pharmaceuticals (NASDAQ: TNXP) is experiencing a stock surge following positive FDA developments, signaling new growth potential for biotech investors. As excitement builds around its CNS therapies, traders should watch regulatory updates for volatility and opportunities.